ACR Image Metrix Formalizes Imaging Biomarker Development Program
ACR Image Metrix has formalized a biomarker and imaging development program.
ACR Image Metrix has partnered with radiopharmacies to overcome the challenging logistics of using radiolabeled tracers as biomarkers in clinical research and has formalized a biomarker imaging development program that includes clinical strategy, trial design and execution.
“ACR Image Metrix has experience and understands the challenges with biomarkers,” stated Michael J. Morales, General Manager. “Our operational expertise and infrastructure ensure our clients’ data meet regulatory requirements. Additionally, we are currently assisting several sponsors with their biomarker clinical development programs in multiple therapeutic categories. This is a new area for sponsors as well as the FDA, and ACR Image Metrix aims to add value to this new frontier in drug development.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
